Aktis Oncology, backed by big‑pharma investors including Eli Lilly, Merck and Bristol Myers Squibb, filed for an IPO to finance its miniprotein radiopharmaceutical programs. The filing noted plans to use proceeds to advance clinical trials of Ac‑AKY‑1189 (Nectin‑4 targeting) and Ac‑AKY‑2519 (B7‑H3 targeting) and to support working capital. Aktis has raised roughly $346 million in private financing and holds partnerships and investments from multiple large pharma firms. The company plans to read out early U.S. phase 1b data for Ac‑AKY‑1189 in 2027 and highlighted potential advantages of imaging‑guided patient selection in radiopharma development. The IPO application tests investor appetite for radiopharma amid a tentative resurgence in biotech public markets and continued pharmaceutical interest in targeted alpha therapeutics.